RESUMEN
BACKGROUND: Almost half of people living with HIV (PLWH) in the USA are over 50 years of age; this is expected to increase to 70% by 2020. Yet, few interventions exist for older PLWH that address psychological and physical symptoms combined, both prevalent in this population. There is a need to find innovative and accessible interventions that can help older PLWH to manage their symptoms. Mind-body interventions, like tai chi/qigong (TCQ), improve both physical and psychological health. TCQ is a series of slow, low-impact meditative movements that integrates breathwork, meditation, and stances. METHODS: The present study is an exploratory clinical trial that will evaluate the acceptability and feasibility of a 12-week, small group TCQ intervention (n = 24), a sham qigong control condition (n = 24), and a standard of care control condition (n = 24) for older people living with HIV/AIDS. It will also explore any preliminary associations between the TCQ intervention and symptom alleviation. Participants will be recruited from community-based health and social services organizations in Miami, FL, and randomized to one of the 3 conditions. DISCUSSION: We will assess feasibility and acceptability through questionnaires and adherence to TCQ. We will assess preliminary associations with symptoms such as depression, anxiety, social support, chronic HIV-related fatigue, and clinical outcomes. These will be described through proportions, means, and changes over time through graphing techniques. Outcomes will be assessed at baseline, at post-intervention, and at 3 months follow-up. These preliminary analyses also will provide information necessary to estimate effect size and power needed for a larger clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov NCT03840525 . Registered on 16 July 2018.
Asunto(s)
Infecciones por VIH , Qigong , Taichi Chuan , Anciano , Infecciones por VIH/diagnóstico , Infecciones por VIH/terapia , Humanos , Terapias Mente-Cuerpo , Calidad de VidaRESUMEN
The onset of various kidney diseases has been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. However, detailed clinical and pathological features are lacking. We screened and analyzed patients with newly diagnosed kidney diseases after inactivated SARS-CoV-2 vaccination in Peking University First Hospital from January 2021 to August 2021, and compared them with the reported cases in the literature. We obtained samples of blood, urine and renal biopsy tissues. Clinical and laboratory information, as well as light microscopy, immunostaining and ultrastructural observations, were described. The SARS-CoV-2 spike protein and nucleoprotein were stained using the immunofluorescence technique in the kidney biopsy samples. SARS-CoV-2 specific antibodies were tested using magnetic particle chemiluminescence immunoassay. The study group included 17 patients with a range of conditions including immune-complex-mediated kidney diseases (IgA nephropathy, membranous nephropathy and lupus nephritis), podocytopathy (minimal change disease and focal segmental glomerulosclerosis) and others (antineutrophil-cytoplasmic-antibody-associated vasculitis, anti-glomerular basement membrane nephritis, acute tubulointerstitial nephritis and thrombotic microangiopathy). Seven patients (41.18%) developed renal disease after the first dose and ten (58.82%) after the second dose. The kidney disease spectrum as well as clinicopathological features are similar across different types of SARS-CoV-2 vaccines. We found no definitive evidence of SARS-CoV-2 spike protein or nucleoprotein deposition in the kidney biopsy samples. Seropositive markers implicated abnormal immune responses in predisposed individuals. Treatment and follow-up (median = 86 days) showed that biopsy diagnosis informed treatment and prognosis in all patients. In conclusion, we observed various kidney diseases following SARS-CoV-2 vaccine administration, which show a high consistency across different types of SARS-CoV-2 vaccines. Our findings provide evidence against direct vaccine protein deposition as the major pathomechanism, but implicate abnormal immune responses in predisposed individuals. These findings expand our understanding of SARS-CoV-2 vaccine renal safety.
RESUMEN
OBJECTIVES: To analyze Australian national data to examine the impact of the coronavirus disease 2019 (COVID-19) pandemic on mental health-related hospital presentations among children and adolescents during the pandemic period with restrictions, and the period after the restrictions eased. METHODS: We analyzed the monthly mental health-related inpatient admissions and emergency department (ED) attendances data from 6 large pediatric hospitals across Australia, using the Bayesian structural time series models. The COVID-19 restriction period was from March 2020 to December 2021 and the COVID-19 restriction-eased period from January to June 2022. RESULTS: A total of 130 801 mental health-related hospital admissions (54 907) and ED attendances (75 894) were analyzed. During the COVID-19 restriction period, there was a significant increase in inpatient admissions related to deliberate self-harm behaviors (82%, 95% credible interval [CrI], 7%-160%) and ED attendances related to overall mental health disorders (15%, 95% CrI, 1.1%-30%) and eating disorders (76%, 95% CrI, 36%-115%). The increase was higher among females and those living in the least socioeconomically disadvantaged areas, suggesting a widening gap between mental health-related presentations by sex and socioeconomic status. After the restrictions eased, there were slight declines in mental health-related hospital presentations; however, the numbers remained higher than the pre-COVID-19 levels. CONCLUSIONS: The increase in mental health-related hospital presentations during the COVID-19 period calls for additional support for pediatric mental health care, particularly for eating disorders and deliberate self-harm among female adolescents. It is important to monitor pediatric mental health service use as we enter "COVID-19 normal" period.
Asunto(s)
COVID-19 , Salud Mental , Adolescente , Humanos , Niño , Femenino , Teorema de Bayes , Australia/epidemiología , COVID-19/epidemiología , COVID-19/terapia , Hospitalización , Servicio de Urgencia en Hospital , Hospitales Pediátricos , Estudios RetrospectivosRESUMEN
Background Since the COVID-19 pandemic, social media has become an important arena for the public to transmit and exchange messages, feelings, opinions, and information about the epidemic. In the era of social media, many UGC contents from self-media and various information about the epidemic on social media have strong emotional colors. These contents are not only rich in resources for text sentiment analysis but also reveal the laws and characteristics of the evolution of users' emotional tendencies in public health emergencies. It even ties together the interaction between media content and society. Objective As the Sina Weibo platform's characteristics of communication are real-time, open, and “many-to-many,” the objective of this study is to collect Weibo-blog contents tagged with the outbreak of COVID-19 in a certain metropolis in China and analyze the emotional evolution situation of Weibo-blogs of the unexpected public health emergency involved. This will provide a dynamic understanding of the mechanisms underlying the evolution of emotional conditions in the context of public health emergencies. Methods This paper uses a Python crawler, the SnowNLP sentiment analysis model, and correlation analysis to calculate the emotional tendencies of the event “Covid-19 outbreak in a Chinese metropolis” on the Sina Weibo platform. The study was carried out in terms of the evolutionary stages of the event and the factors which induce it. Results This paper revealed characteristics of time-varying laws and dynamic propagation of users' emotional evolution in public health emergencies. (1) This study refers to the life cycle model of COVID-19, combined with the statistics of the time series of the quantities of Weibo-blog posting, and divides the law of the quantities of Weibo-blog posting changing with the event into three stages: outbreak period, stalemate period, and resolution period. (2) Users' emotional tendencies are changeable and unstable which are easily induced by various factors. (3) There is a significant positive correlation between the reported confirmed cases and the quantities of Weibo-blog posts. (4) Individual emotional tendencies will have a positive changing trend with the public's average emotional tendencies after the event occurs. (5) There is no correlation between reposts, comments, and Weibo-blog emotional tendencies. Conclusion The research found that, given staged evolution and repeated fluctuations of emotional tendencies, relevant departments should effectively use this law and set up different response plans according to different stages. In addition, what is highly coupled with users' emotional tendencies is not only the information about the virus but more large-scale infected by different intensities of emotions.
RESUMEN
Public health measures to mitigate the COVID-19 pandemic have altered health care for chronic conditions. The impact of the COVID-19 pandemic on paediatric asthma, the most common chronic respiratory cause of childhood hospitalisation, in Australia, remains unknown. In a multicentre study, we examined the impact of three waves of COVID-19 on paediatric asthma in New South Wales Australia. Time series analysis was performed to determine trends in asthma hospital presentations in children aged 2-17 years before (2015-2019) and during the COVID-19 pandemic (2020-2021) using emergency department and hospital admission datasets from two large tertiary paediatric hospitals.In this first report from Australia, we observed a significant decrease in asthma hospital presentations during lockdown periods including April (68.85%), May (69.46%), December (49.00%) of 2020 and August (66.59%) of 2021 compared to pre-pandemic predictions.The decrease in asthma hospital presentations coincided with the lockdown periods during first, second and third waves of the COVID-19 pandemic and was potentially due to reduced transmission of other common respiratory viruses from restricted movement.
RESUMEN
Online live streaming has been widely used in distant teaching, online live shopping, and so on. Particularly, online teaching live streaming breaks the time and space boundary of teaching and has better interactivity, which is a new distant education mode. As a new online sales model, online live shopping promotes the rapid development of Internet economy. However, the quality of live video affects the user experience. This paper studies the optimization algorithm of ultra-high-definition live streaming, focusing on superresolution technology. Convolutional neural network (CNN) is a multilayer artificial neural network designed to process two-dimensional input data. It takes advantage of CNN in image processing. This paper proposes an image superresolution algorithm based on hybrid dilated convolution and Laplacian pyramid. By mixing the dilated convolution module, the receptive field of the network can be improved more effectively to obtain more context information so that the high-frequency features of the image can be extracted more effectively. Experiment was running on Set5, Set14, Urban100, and BSD100 datasets, and the results reveal that the proposed algorithm outperforms baselines with respect to peak signal to noise ratio (PSNR), structural similarity index measurement (SSIM), and image quality.
RESUMEN
Condition:
Novel Coronavirus Pneumonia (COVID-19)Intervention:
The vaccine 50 µg group:1 dose of 50 µg test vaccine was administered intramuscularly on days 0 and 28 respectively;The vaccine 100 µg group:1 dose of 100 µg test vaccine was administered intramuscularly on days 0 and 28 respectively;Control group:placebo;Primary outcome:
Levels of SARS-CoV-2 novel coronavirus S protein antibody (IgG);Levels of SARS-CoV-2 novel coronavirus neutralizing antibodies;Criteria:
Inclusion criteria: 1. The age at the time of the first dose of the vaccine is 18-59 years old, and the gender is not limited;2. The subject has full capacity for civil conduct;
3. Axillary body temperature is less than 37.3 ? on the day of enrollment;
4. Subjects have independent judgment ability, can read, understand and complete vaccination diary cards, and they participate voluntarily and sign an informed consent form.
Exclusion criteria: 1. The subject has contact history with SARS-CoV-2 infected person (positive for nucleic acid test) or suspected infected person within 14 days;
2. Have a history of severe allergy to any vaccine, food or medicine, such as urticaria, anaphylactic shock, eczema, allergic dyspnea, angiopathic edema, etc.;
3. Subjects have a history of allergy to any of the components of the study vaccine (SARS-CoV-2 mRNA, Dlin-MC3-DMA, cholesterol, distearyl phosphatidylcholine, PEG2000-DMG, phosphoric acid buffer);
4. Have a history of SARS virus infection;
5. Subjects with medical history or family history of epileptic convulsions, nervous system diseases and mental diseases;
6. A history of hospital-diagnosed thrombocytopenia or other coagulation disorders before enrollment;
7. The researchers judged known or suspected co-occurrence of more severe diseases, including: Respiratory disease, tuberculosis, acute infection or chronic disease activity, liver and kidney disease, cardiovascular disease (cardiopulmonary failure), drug-uncontrolled hypertension (systolic blood pressure >=160mmHg, diastolic blood pressure >= 100mmHg), malignant tumor, infection or allergic skin disease, HIV infection (test report can be provided);
8. Congenital malformation, developmental disorders, or chronic diseases (such as Down syndrome, diabetes mellitus, sickle cell anemia or neurological disorders, Guillain-Barre syndrome) that the researchers have determined are not suitable for participation in this study;
9. Subjects with known impairment or low immunological function diagnosed by the hospital before enrollment;
10. Evidence of tobacco, alcohol and drug abusers;
11. Positive SARS-CoV-2 nucleic acid test and/or positive antibody test before the first dose of vaccine;
12. Female: those who have a positive urine pregnancy test, are pregnant, breastfeeding, or have a pregnancy plan within 1 year; Male: whose spouse plans to become pregnant within 1 year;
13. Using any other investigational or unregistered product (drug, biological product or device) prior to the first dose of the vaccine, or planning to use it during the study;
14. Subjects receiving immunoenhancement or immunosuppressive therapy within 6 months prior to the first dose of vaccine (continuous oral or intravenous infusion for more than 14 days);
15. Have been diagnosed with congenital or acquired immunodeficiency or suspected systemic diseases that may interfere with the conduct or completion of the study, such as tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus (HIV), syphilis infection, etc.;
16. Those who received whole blood, plasma and immunoglobulin treatment in the six months prior to the first dose of vaccine;
17. Other inactivated vaccines were administered within 14 days and live attenuated vaccines within 28 days prior to the first dose;
18. Taking antipyretic, analgesic and antiallergic drugs within 3 days prior to enrollment;
19. Subjects who, in the investigator's judgment, are unable to comply with study procedures, follow protocol, or plan to permanently relocate from the area prior to the end of the study, or plan to leave the area for an extended period of time during the scheduled visit;
20. Relevant staff members participating in the study themselves or their immediate family members (e.g. spouse, parents, siblings or children);
21. In the investigator's judgment, there are other conditions that are not appropriate for participation in this clinical
RESUMEN
BACKGROUND: The first wave of the COVID-19 pandemic hit New South Wales (NSW) Australia in early 2020, followed by a sharp state-wide lockdown from mid-March to mid-May. After the lockdown, there had been a low level of community transmission of COVID-19 over a year. Such pandemic experiences provide unique opportunity to understand the impact of the pandemic on paediatric health service use as countries emerge from the pandemic. METHODS: We examined the difference between the observed and the predicted numbers of inpatient admissions and emergency department (ED) attendances, respectively, related to chronic, acute infectious and injury conditions, for each month during the COVID-19 period (January 2020-February 2021), based on the numbers from 2016 to 2019, using records from two major paediatric hospitals in NSW. All analyses were conducted using autoregressive error models and were stratified by patient age, sex and socioeconomic status. FINDINGS: Health service use was significantly lower than predicted for admissions and/or ED attendances related to chronic conditions, acute infections, and injury during the lockdown in 2020. Change in health service use varied by chronic conditions, from the largest decrease for respiratory conditions (40-78%) to non-significant change for cancer and mental health disorders. After the lockdown, health service use for most health conditions returned to pre-COVID-19 predicted levels. However, for mental health disorders, increased health service use persisted from June 2020 up to February 2021 by 30-55%, with higher increase among girls aged 12-17 years and those from socioeconomically advantaged areas. There was persistently lower health service use for acute infections and increased health service use for injuries. Differences by socio-demographic factors were noted for mental health disorders and injuries. INTERPRETATION: The immediate return to pre-COVID-19 levels for most chronic conditions after the first lockdown in NSW highlights the healthcare needs for children affected by chronic conditions. Persistently lower health service use for acute infections is likely attributable to the decreased social contact. Sustained and targeted mental health support is essential to address the potentially increased demand for services among children during and beyond the pandemic. FUNDING: Financial Markets Foundation for Children Chair (RL, NN), NHMRC Investigator Grant (APP1197940) (NN), NHMRC Career Development fellowship (GNT1158954) (SW).
RESUMEN
By developing a machine learning-based measure of corporate big data strategies, this study empirically explores how stock markets respond to the COVID-19 pandemic and whether corporate big data strategies make firms immune to the pandemic effect. We find that except for information technology and health care sectors, firms in most sectors in China are negatively affected by the COVID-19 outbreak. Among these firms, an increase in the number of daily new confirmed cases in the city of a firm's headquarters is associated with a decrease in its stock prices, however, such a decline is attenuated for firms with a high emphasis on big data strategies. Our results are robust when we use COVID-19 cases at the whole country level.
RESUMEN
Condition:
Novel Coronavirus Pneumonia (COVID-19)Intervention:
Experimental group:test vaccine;Control group:placebo;Primary outcome:
SARS-CoV-2 neutralizing antibody;RBD protein binding antibody (IgG) ;Criteria:
Inclusion criteria: 1. Aged 3-17 years (both inclusive);2. The subject voluntarily agrees to participate in the research (or the subject's legal guardian voluntarily agrees that the child participates in the research), the guardian and the subject (8-17 years old) sign the informed consent form, and can provide valid identification; comply with the requirements of the test protocol;
3. The subject and/or the subject's legal guardian has the ability to understand (non-literate) research procedures and to participate in planned follow-up visits;
4. Underarm body temperature <37.3? (>14 years old), armpit body temperature <37.5? (<=14 years old);
5. Subjects of childbearing age agree to take effective contraceptive measures during the study.
Exclusion criteria: 1. The results of physical examination and laboratory examination before screening are abnormal and clinically significant as determined by the clinician;
2. History of severe allergy to any component of the trial vaccine, including aluminum preparations, such as: anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), dyspnea, angioedema, etc.; or have a history of the above-mentioned serious side effects after using any vaccines or drugs in the past;
3. Those with a history of SARS and SARS-CoV-2 (meet any of the following: (1) Have a history of SARS and SARS-CoV-2 infection or disease in the past; (2) During the current SRAS-CoV-2 epidemic, there is a history of contact with confirmed/suspected patients of the new crown; (3) Detection of SARS-CoV-2 IgM and/or IgG antibody positive; (4) Real-time fluorescent RT-PCR nucleic acid positive;);
4. Antipyretics or pain relievers have been taken within 24 hours before the first dose of vaccination;
5. Those who have been vaccinated against the new coronavirus, or subunit vaccine and/or inactivated vaccine within 14 days before the first dose of vaccine, and live attenuated vaccine within 30 days;
6. Those suffering from the following diseases:
(1) Acute (within 72 hours) febrile illness (aged >14 years, armpit temperature >=37.3?; aged <=14 years, armpit temperature >=37.5?);
(2) Digestive system diseases (such as diarrhea, abdominal pain, vomiting, etc.) in the past 7 days;
(3) Suffering from congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
(4) History of congenital or acquired immunodeficiency or autoimmune disease or receiving immunomodulatory treatment within 6 months, such as immunosuppressive dose of glucocorticoid (dose reference: equivalent to prednisone 20mg/day, more than a week); or monoclonal antibody; or thymosin; or interferon;
(5) Known to be diagnosed with infectious diseases, such as: active tuberculosis, viral hepatitis patients and/or human immunodeficiency virus HIV antibody positive or syphilis-specific antibody positive or parents are HIV-infected;
(6) Neurological diseases or neurodevelopmental disorders (eg, migraine, epilepsy, stroke, seizure within the last three years, encephalopathy, focal neurological deficit, Guillain-Barre syndrome, encephalomyelitis, or transverse myelitis); psychiatric or family history;
(7) Functional asplenia, as well as asplenia or splenectomy due to any cause;
(8) Patients with serious chronic diseases or in advanced stages that cannot be controlled smoothly, such as diabetes and thyroid diseases;
(9) Severe liver and kidney disease; current respiratory disease requiring daily drug treatment (eg, chronic obstructive pulmonary disease [COPD], asthma) or any treatment for exacerbation of respiratory disease (eg, asthma exacerbation) within the past 5 years; a history of severe cardiovascular disease (eg, congestive heart failure, cardiomyopathy, ischemic heart disease, arrhythmia, conduction block, myocardial infarction, cor pulmonale) or myocarditis or pericarditis;
(10) Thrombocytopenia, any coagulation disorder or receiving anticoagulant treatment, etc.;
(11) Cancer patients;
7. Received blood or blood-related products, including immune globulin, within 3 months; or planned to use it during the study;
8. Those who are pregnant (including positive urine pregnancy test), or are breastf
Asunto(s)
Betacoronavirus/aislamiento & purificación , Salud Infantil/tendencias , Control de Enfermedades Transmisibles , Infecciones por Coronavirus , Hospitalización , Pandemias , Neumonía Viral , Virus Sincitial Respiratorio Humano/aislamiento & purificación , Infecciones del Sistema Respiratorio , Australia/epidemiología , COVID-19 , Niño , Control de Enfermedades Transmisibles/métodos , Control de Enfermedades Transmisibles/organización & administración , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Transmisión de Enfermedad Infecciosa/prevención & control , Registros Electrónicos de Salud/estadística & datos numéricos , Hospitalización/estadística & datos numéricos , Hospitalización/tendencias , Humanos , Pandemias/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Salud Pública/tendencias , Infecciones del Sistema Respiratorio/epidemiología , Infecciones del Sistema Respiratorio/terapia , Infecciones del Sistema Respiratorio/virología , SARS-CoV-2Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por Coronavirus/psicología , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/psicología , Neumonía Viral/psicología , Estrés Psicológico , Anciano , Anciano de 80 o más Años , Betacoronavirus , COVID-19 , Infecciones por Coronavirus/epidemiología , Femenino , Florida/epidemiología , Infecciones por VIH/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/epidemiología , Distrés Psicológico , SARS-CoV-2RESUMEN
Condition:
cancerIntervention:
Group 2:thymosin;Group 1:BaZhen soup;Primary outcome:
postoperative complication;occupancy rate of intensive care unit;2-year tumor-free survival and overall survival;Criteria:
Inclusion criteria: (1) aged 18-60 years;(2) BMI in the normal range (1+/-20%);
(3) diagnosis of lung cancer, breast cancer, cervical cancer, colorectal cancer, with surgical indications, no distant metastasis;
(4) ASA grade I-II;
(5) no thymosin A1, Chinese Medicine (Bazhen Tang) use contraindications;
(6) before the test, the patients or their legal representatives understand and voluntarily sign the ethics Informed consent approved by the Committee.
Exclusion criteria: (1) had participated in other clinical trials within 4 weeks before the start of this study;
(2) used albumin and immunoenhancer drugs within 15 days before operation;
(3) had a history of coronavirus infection, direct or indirect exposure, had fever, cough;
(4) had previous immune deficiency;
(5) had congenital metabolic abnormalities and other diseases;
(6) Patients with autoimmune diseases and infections;
(7) pregnant and lactating women;
(8) who were not willing to participate in the study for any reason.
RESUMEN
Condition:
cancerIntervention:
Group 2:thymosin;Group 1:BaZhen soup;Primary outcome:
postoperative complication;2-year tumor-free survival and overall survival;occupancy rate of intensive care unit;Criteria:
Inclusion criteria: (1) aged 18-60 years;(2) BMI in the normal range (1+/-20%);
(3) diagnosis of lung cancer, breast cancer, cervical cancer, colorectal cancer, with surgical indications, no distant metastasis;
(4) ASA grade I-II;
(5) no thymosin A1, Chinese Medicine (Bazhen Tang) use contraindications;
(6) before the test, the patients or their legal representatives understand and voluntarily sign the ethics Informed consent approved by the Committee.
Exclusion criteria: (1) had participated in other clinical trials within 4 weeks before the start of this study;
(2) used albumin and immunoenhancer drugs within 15 days before operation;
(3) had a history of coronavirus infection, direct or indirect exposure, had fever, cough;
(4) had previous immune deficiency;
(5) had congenital metabolic abnormalities and other diseases;
(6) Patients with autoimmune diseases and infections;
(7) pregnant and lactating women;
(8) who were not willing to participate in the study for any reason.
RESUMEN
Condition:
novel coronavirus pneumonia (COVID-19)Intervention:
Case series:Nil;Primary outcome:
clincical characteristics;Criteria:
Inclusion criteria: Severe patients diagnosed with novel coronavirus pneumonia (COVID-19) in Huanggang City, and admitted to the Dabie mountain regional treatment center in huanggang from Jan.28th,2020 to Mar.12th,2020.Exclusion criteria: Patients who died within 24h after admission.
RESUMEN
Condition:
Novel Coronavirus Pneumonia (COVID-19)Intervention:
Control group:Western medicine treatment;Experimental group:integrate Chinese and conventional medicine treatment;Primary outcome:
TCM syndrome;Criteria:
Inclusion criteria: The diagnostic criteria of novel coronavirus infection pneumonia can be observed and agreed by the patients themselves.Exclusion criteria: pregnant or lactating women
RESUMEN
BACKGROUND: Since the first case of a novel coronavirus (COVID-19) infection pneumonia was detected in Wuhan, China, a series of confirmed cases of the COVID-19 were found in Beijing. We analyzed the data of 262 confirmed cases to determine the clinical and epidemiological characteristics of COVID-19 in Beijing. METHODS: We collected patients who were transferred by Beijing Emergency Medical Service to the designated hospitals. The information on demographic, epidemiological, clinical, laboratory test for the COVID-19 virus, diagnostic classification, cluster case and outcome were obtained. Furthermore we compared the characteristics between severe and common confirmed cases which including mild cases, no-pneumonia cases and asymptomatic cases, and we also compared the features between COVID-19 and 2003 SARS. FINDINGS: By Feb 10, 2020, 262 patients were transferred from the hospitals across Beijing to the designated hospitals for special treatment of the COVID-19 infected by Beijing emergency medical service. Among of 262 patients, 46 (17.6%) were severe cases, 216 (82.4%) were common cases, which including 192 (73.3%) mild cases, 11(4.2%) non-pneumonia cases and 13 (5.0%) asymptomatic cases respectively. The median age of patients was 47.5 years old and 48.5% were male. 192 (73.3%) patients were residents of Beijing, 50 (26.0%) of which had been to Wuhan, 116 (60.4%) had close contact with confirmed cases, 21 (10.9%) had no contact history. The most common symptoms at the onset of illness were fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%) and headache (6.5%). The median incubation period was 6.7 days, the interval time from between illness onset and seeing a doctor was 4.5 days. As of Feb 10, 17.2% patients have discharged and 81.7% patients remain in hospital in our study, the fatality of COVID-19 infection in Beijing was 0.9%. INTERPRETATION: On the basis of this study, we provided the ratio of the COVID-19 infection on the severe cases to the mild, asymptomatic and non-pneumonia cases in Beijing. Population was generally susceptible, and with a relatively low fatality rate. The measures to prevent transmission was very successful at early stage, the next steps on the COVID-19 infection should be focused on early isolation of patients and quarantine for close contacts in families and communities in Beijing. FUNDING: Beijing Municipal Science and Technology Commission and Ministry of Science and Technology.
Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/fisiopatología , Neumonía Viral/epidemiología , Neumonía Viral/fisiopatología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Beijing/epidemiología , COVID-19 , Niño , Preescolar , Tos , Brotes de Enfermedades , Fatiga , Femenino , Fiebre , Humanos , Lactante , Masculino , Persona de Mediana Edad , Pandemias , Estudios Retrospectivos , SARS-CoV-2 , Síndrome Respiratorio Agudo Grave/epidemiología , Enfermedad Relacionada con los Viajes , Adulto JovenRESUMEN
Condition:
Novel Coronavirus Pneumonia (COVID-19)Intervention:
Case series:moxibustion;Primary outcome:
mood assessment;Criteria:
Inclusion criteria: Moxibustion intervention study plan for 14 days of NCP close contact with forced home isolation:Participants inclusion criteria:
1. Aged 18 to 75 years old;
2. Those that meet one or more of the following:
(1)In the past 1 month, there is a history of contact with patients with pneumonia diagnosed by new coronavirus;
(2) People who have lived or stayed in Wuhan or the affected area in the past month;
3. Those who have had close contacts with returnees from Hubei in the past month;
4. Persons who live or work in 2 or more confirmed cases of novel coronavirus infection pneumonia;
5. Take the same transportation with the newly diagnosed cases of Novel Coronary Pneumonia and have close contact with people, including those who have taken care of the patient on the transportation and the patient's colleagues (family, colleagues, friends, etc.);
6. The area is limited to Hunan Province;
7. Voluntarily participate in this research and sign the informed consent.
Patient who meet the above 4 items can be included in this study.
Research Program on Moxibustion Intervention in NCP Home Isolation Population:
1. Aged 18 to 75 years old;
2. Those that meet one or more of the following:
(1) There is no contact history of patients with pneumonia diagnosed with new-type coronavirus in the past month;
(2) The corpus callosum is weak, susceptible to wind and cold, and has a history of chronic respiratory diseases;
3. The area is limited to Hunan Province;
4. Voluntarily participate in this research and sign the informed consent.
Patient who meet the above 4 items can be included in this study.
Research Program on Moxibustion Intervention in NCP Home Isolation Medical Care Group:
1. Aged 18 to 75 years old;
2. Those that meet one or more of the following:
(1) Occupation is doctor and patient;
(2) There is no contact history of patients with pneumonitis diagnosed with new-type coronavirus in the past 1 month;
3. The area is limited to Hu'nan Province;
4. Voluntarily participate in this research and sign the informed consent.
Participants who meet the above 4 items can be included in this study.
Exclusion criteria: (1) Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system;
(2) Those with malignant changes in the lungs;
(3) Persons with a mental, intellectual or language impairment;
(4) pregnant women, lactating women and those who have pregnancy requirements in the last 6 months;
(5) Those who are unable to fill in the questionnaire materials using mobile phones, computers, etc.;
(6) Those who are unwilling to receive moxibustion, or who are allergic to moxibustion or Wenwen cream;
(7) Those who are participating in other clinical trials.
Patients who meet any of the above are excluded.
RESUMEN
Condition:
Novel Coronavirus Pneumonia (COVID-19)Intervention:
Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;Primary outcome:
TCM syndrome;Criteria:
Inclusion criteria: The diagnostic criteria of novel coronavirus infection pneumonia can be observed and agreed by the patients themselves.Exclusion criteria: pregnant or lactating women